Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$23.04 USD
-0.51 (-2.17%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $23.07 +0.03 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
RNA 23.04 -0.51(-2.17%)
Will RNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Other News for RNA
FYBR, BCRX and SABR are among after hour movers
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Where Avidity Biosciences Stands With Analysts
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
RNA January 2025 Options Begin Trading